Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05808478

Eye-tracking Technology for Severe Communication Disability

Augmentative Alternative Communication Intervention Delivered Via Eye-tracking Technology

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
IRCCS Centro Neurolesi Bonino Pulejo · Academic / Other
Sex
All
Age
3 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The aim of this project is to develop an Augmentative and Alternative Communication intervention through the use of Eye tracker system.

Detailed description

The term "complex communication needs" includes all patients who present severe disturbances in speech and language production and/or in comprehension, in relation to oral or written communication modalities. The main purpose of Augmentative and Alternative Communication (AAC) is to promote the best possible communication for people with complex communication needs, through the use of techniques, methods and tools aimed not at replacing pre-existing communication methods but at increasing skills of natural communication through the enhancement of present skills. The Eye tracker system, thanks to allows the recording and analysis of eye movements, could be used successfully to support communication in patients with severe communication disability. The goal of this study is to develop an efficacy Augmentative and Alternative Communication intervention using eye-tracking technology for patients with severe communication disability. The secondary objective was to examine the psychosocial impact of technology for AAC on parents' perspectives and quality of life.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAAC + Eye TrackingThe AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
BEHAVIORALAACTreatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.

Timeline

Start date
2022-01-22
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2023-04-11
Last updated
2023-04-11

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05808478. Inclusion in this directory is not an endorsement.